A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Healthy Clinical Trial

Official title:

A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00868361
• Other study ID #: TAL-MB-100
• Status: Terminated
• Phase: Phase 1
• First received: March 24, 2009
• Last updated: September 15, 2009
• Start date: May 2009
• Est. completion date: September 2009

Study information

• Verified date: September 2009
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: September 2009
• Est. primary completion date: September 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Males, between 18 and 55 years of age, inclusive

• Body Mass Index range 18.0 to 30.0 kg/m2, inclusive

• Have NAT2 slow or rapid acetylator genotype

• In good health as determined by the investigator

• Negative test for selected drugs of abuse at screening

• Negative screens for Hepatitis B, Hepatitis C and HIV

• Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge

• Able to comprehend and willing to sign an Informed Consent Form

• Have 1 to 2 bowel movements per day

Exclusion Criteria:

• Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder

• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance

• History of stomach or intestinal surgery or resection

• History or presence of an abnormal ECG,

• History of clinically significant alcohol or drug use within 1 year prior to Check-in

• Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in

• Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in

• Use of any drugs which may interact with the study drug within 30 days prior to Check-in

• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in

• Use of any prescription medications/products within 14 days prior to Check in

• Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in

• Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in

• Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in

• Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion

• Receipt of blood products within 2 months prior to Check-in

• Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Talampanel (non-radiolabeled), [14C] Talampanel
50 mg capsule single dose

Locations

Country	Name	City	State
United States	Covance Clinical Pharmacology Inc.	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Teva Pharmaceutical Industries	Covance

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the mass balance of [14C]-talampanel. To characterize the metabolism of [14C] talampanel in plasma, feces, and urine. To assess the pharmacokinetics (PK) of total radioactivity, talampanel, and N-acetyl talampanel.		6-9 days	No
Secondary	To explore the effect of N-acetyltransferase 2 (NAT2) genotype on the PK and metabolism of [14C] talampanel. To further assess the safety and tolerability of talampanel.		6-9 days	Yes